Extended Data Fig. 3: Flow Cytometry Gating Strategy.

CD34+ HSPCs from day 1 apheresis products collected following treatment of patients with MM with G-CSF plus either placebo, plerixafor or motixafortide were purified by immunomagnetic selection and evaluated by multicolor FACS. Gating strategy used to define nine different CD34+ HSPC subsets is shown.